Parkinson's disease patients first treated at age 75 years or older: Acomparative study

Parkinsonism and Related Disorders

Volumn 20, Issue 1, 2014, Pages 69-74

  Peretz, Chava ^a   Chillag Talmor, Orly ^b   Linn, Shai ^b   Gurevich, Tanya ^a   El Ad, Baruch ^c   Silverman, Barbara ^c   Friedman, Nurit ^c   Giladi, Nir ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b UNIVERSITY OF HAIFA   (Israel)

^c MACCABI HEALTHCARE SERVICES   (Israel)

Author keywords

Age at first treatment; Anti parkinsonian drugs; Parkinson's disease; Survival

Indexed keywords

LEVODOPA;

AGE; AGED; ARTICLE; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE DURATION; FEMALE; HUMAN; ISRAEL; MAJOR CLINICAL STUDY; MALE; MORTALITY; PARKINSON DISEASE; PRIORITY JOURNAL; SEX DIFFERENCE; TIME TO TREATMENT; TREATMENT OUTCOME; VERY ELDERLY;

AGE AT FIRST TREATMENT; ANTI-PARKINSONIAN-DRUGS; PARKINSON'S DISEASE; SURVIVAL;

AGE OF ONSET; AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE;

EID: 84892789618     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2013.09.020     Document Type: Article

References (26)

1. Van Rooden S.M., Heiser W.J., Kok J.N., Verbaan D., van Hilten J.J., Marinus J. The identification of Parkinson's disease subtypes using cluster analysis: a systematic review. Mov Disord 2010, 25:969-978.
2. Lees A.J., Hardy J., Revesz T. Parkinson's disease. Lancet 2009, 373:2055-2066.
3. Horsfall L., Petersen I., Walters K., Schrag A. Time trends in incidence of Parkinson's disease diagnosis in UK primary care. JNeurol 2013, 260:1351-1357.
4. Diem-Zangerl A., Seppi K., Wenning G.K., Poewe W. Mortality in Parkinson's disease: a 20-year follow-up study. Mov Disord 2009, 24:819-825.
5. Herlofson K., Lie S.A., Arsland D., Larsen J.P. Mortality and Parkinson disease: a community based study. Neurology 2004, 62:937-942.
6. Posada I.J., Benito-León J., Louis E.D., Trincado R., Villarejo A., Medrano M.J., et al. Mortality from Parkinson's disease: a population-based prospective study (NEDICES). Mov Disord 2011, 26:2522-2529.
7. Hart R.G., Pearce L.A., Ravina B.M., Yaltho T.C., Marler J.R. Neuroprotection trials in Parkinson's disease: systematic review. Mov Disord 2009, 24:647-654.
8. Post B., Speelman J.D., de Haan R.J. CARPA-study group. Clinical heterogeneity in newly diagnosed Parkinson's disease. JNeurol 2008, 255:716-722.
9. Nagayama H., Ueda M., Kumagai T., Tsukamoto K., Nishiyama Y., Nishimura S., et al. Influence of ageing on the pharmacokinetics of levodopa in elderly patients with Parkinson's disease. Parkinsonism Relat Disord 2011, 17:150-152.
10. Israel Central Bureau of Statistics. http://www.cbs.gov.il/reader/cw_usr_view_SHTML?ID=591.
11. Kowal S.L., Dall T.M., Chakrabarti R., Storm M.V., Jain A. The current and projected economic burden of Parkinson's disease in the United States. Mov Disord 2013, 28:311-318.
12. Diederich N.J., Moore C.G., Leurgans S.E., Chmura T.A., Goetz C.G. Parkinson disease with old-age onset: a comparative study with subjects with middle-age onset. Arch Neurol 2003, 60:529-533.
13. Chillag-Talmor O., Giladi N., Linn S., Gurevich T., El-Ad B., Silverman B., et al. Use of a refined drug tracer algorithm to estimate prevalence and incidence of Parkinson's disease in a large Israeli population. JParkinsons Dis 2011, 1:35-47.
14. Chillag-Talmor O., Giladi N., Linn S., Gurevich T., El-Ad B., Silverman B., et al. Estimation of Parkinson's disease survival in Israeli men and women, using health maintenance organization pharmacy data in a unique approach. JNeurol 2013, 260:62-70.
15. Wei Y.J., Stuart B., Zuckerman I.H. Use of antiparkinson medications among elderly Medicare beneficiaries with Parkinson's disease. Am J Geriatr Pharmacother 2010, 8:384-394.
16. Wang X., You G., Chen H., Cai X. Clinical course and cause of death in elderly patients with idiopathic Parkinson's disease (Chinese). Chin Med J (Engl) 2002, 115:1409-1411.
17. Fall P.A., Saleh A., Fredrickson M., Olsson J.E., Granérus A.K. Survival time, mortality, and cause of death in elderly patients with Parkinson's disease: a 9-year follow-up. Mov Disord 2003, 18:1312-1316.
18. Lai B.C., Schulzer M., Marion S., Teschke K., Tsui J.K. The prevalence of Parkinson's disease in British Columbia, Canada, estimated by using drug tracer methodology. Parkinsonism Relat Disord 2003, 9:233-238.
19. Driver J.A., Kurth T., Buring J.E., Gaziano J.M., Logroscino G. Parkinson disease and risk of mortality: a prospective comorbidity-matched cohort study. Neurology 2008, 70:1423-1430.
20. Chen H., Zhang S.M., Schwarzschild M.A., Hernán M.A., Ascherio A. Survival of Parkinson's disease patients in a large prospective cohort of male health professionals. Mov Disord 2006, 21:1002-1007.
21. Doi Y., Yokoyama T., Nakamura Y., Nagai M., Fujimoto K., Nakano I. How can the national burden of Parkinson's disease comorbidity and mortality be estimated for the Japanese population?. JEpidemiol 2011, 21:211-216.
22. Fernandez H.H., Lapane K.L. Predictors of mortality among nursing home residents with a diagnosis of Parkinson's disease. Med Sci Monit 2002, 8:CR241-CR246.
23. Cereda E., Barichella M., Pedrolli C., Klersy C., Cassani E., Caccialanza R., et al. Diabetes and risk of Parkinson's disease: a systematic review and meta-analysis. Diabetes Care 2011, 34:2614-2623.
24. Pavon J.M., Whitson H.E., Okun M.S. Parkinson's disease in women: a call for improved clinical studies and for comparative effectiveness research. Maturitas 2010, 65:352-358.
25. Rubin S.M. Parkinson's disease in women. Dis Mon 2007, 53:206-213.
26. Haaxma C.A., Bloem B.R., Borm G.F., Oyen W.J., Leenders K.L., Eshuis S., et al. Gender differences in Parkinson's disease. JNeurol Neurosurg Psychiatr 2007, 78:819-824.